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Duchenne Muscular Dystrophy (DMD) is a fatal skeletal muscle wasting disease presenting with excessive
myoﬁbre necrosis and increased inﬂammation and oxidative stress. In the mdx mouse model of DMD,
homeostasis of the amino acid taurine is altered, and taurine administration drastically decreases muscle
necrosis, dystropathology, inﬂammation and protein thiol oxidation. Since the severe pathology of the Golden
Retriever Muscular Dystrophy (GRMD) dog model more closely resembles the human DMD condition, we
aimed to assess the generation of oxidants by inﬂammatory cells and taurine metabolism in this species. In
muscles of 8 month GRMD dogs there was an increase in the content of neutrophils and macrophages, and an
associated increase in elevated myeloperoxidase, a protein secreted by neutrophils that catalyses production of
the highly reactive hypochlorous acid (HOCl). There was also increased chlorination of tyrosines, a marker of
HOCl generation, increased thiol oxidation of many proteins and irreversible oxidative protein damage. Taurine,
which functions as an antioxidant by trapping HOCl, was reduced in GRMD plasma; however taurine was
increased in GRMD muscle tissue, potentially due to increased muscle taurine transport and synthesis. These
data indicate a role for HOCl generated by neutrophils in the severe dystropathology of GRMD dogs, whichmay
be exacerbated by decreased availability of taurine in the blood. These novel data support continued research
into the precise roles of oxidative stress and taurine in DMD and emphasise the value of the GRMD dogs as a
suitable pre-clinical model for testing taurine as a therapeutic intervention for DMD boys.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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rill).1. Introduction
Duchenne Muscular Dystrophy (DMD) is a lethal, X-chromo-
some linked muscle disease affecting about 1 in 3500–6000 boys
worldwide (Reviewed in [1,2]). DMD is characterised by severe
muscle weakness caused by mutations in the dystrophin gene,
which result in the loss of functional dystrophin protein. In ske-
letal muscles this defect increases susceptibility to sarcolemma
damage after muscle contraction leading to myoﬁbre necrosis,
with inﬂammation and excessive ﬁbrosis initially associated with
muscle regeneration [3–5]. Repeated cycles of widespread myo-
ﬁbre necrosis and progressive failure of regeneration over time in
DMD boys (with replacement of myoﬁbres by fatty and ﬁbrous
connective tissue) lead to the loss of muscle mass and function
with premature death of DMD boys, often due to respiratory or
cardiac failure (Reviewed in [1,5,6]).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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animal models of DMD) are not fully understood, disturbed in-
tracellular calcium homeostasis, inﬂammation and oxidative stress
are implicated [7,8]. Proposed sources of various oxidants in dys-
trophic muscle include mitochondria, inﬂammatory cells, NAD(P)H
oxidase, xanthine oxidase, and decoupling of NOS (via dislocation
or translocation of nNOS from the dystroglycan complex of the
sarcolemma) (reviewed in [9]). Oxidative damage to muscle pro-
teins has been observed in both DMD boys and the widely studied
mdx mouse model of DMD [10–14]. Another major cellular con-
sequence of oxidant exposure is the reversible oxidation of protein
thiol side chains (-SH, in the cysteine residue). Protein thiols can
undergo numerous reactions, which are dependent on the species
and concentration of oxidants they encounter [15]. For example,
oxidants such as hydrogen peroxide, can cause reversible oxida-
tion (disulphide formation) of thiols, for which the reduction/
oxidation (redox) state is an important regulator of protein func-
tion [16]. We have previously shown that reversible protein thiol
oxidation is increased inmdxmuscle, and is especially pronounced
around areas of necrosis, occurring on muscle proteins such as
myosin heavy chain, myosin light chain and tropomyosin, as well
as on glycolytic proteins phosphoglycerate mutase and triose-
phosphate isomerase [14,17–22].
Antioxidants that target protein thiol oxidation, such as the
cysteine/glutathione precursors n-acetylcysteine (NAC) and L-2-
Oxothiazolidine-4-Carboxylate (OTC) have been investigated in
mdx mice as therapeutic interventions for DMD [19,20,23–26].
Treatment of mdx mice with NAC or OTC reduces muscle pathol-
ogy, as shown by decreased myoﬁbre necrosis, inﬂammatory cells
and TNF levels, and improved grip strength [19,20,23–25]. NAC
and OTC are derivatives of the amino acid cysteine, and can in-
crease tissue content of both cysteine and GSH, two major cellular
thiol antioxidants [27,28]. However we established that the me-
chanism of action of NAC and OTC in mdx mice was not via an
increase in either cysteine or glutathione in muscle, liver and
plasma [19,20,23]. Instead, we showed that OTC treatment of mdx
mice leads to an increase in the content of the semi-essential
amino acid taurine (2-aminoethanesulfonic acid) in muscle, liver
and plasma [19,23].
Taurine is synthesised from cysteine, as a mechanism for re-
moving excess cysteine, which is toxic in mammals [29,30].
Taurine is found in many tissues and is considered important for
the function of skeletal muscle; the concentration of taurine in
tissues is regulated by interactions between dietary intake, bio-
synthetic rate (mainly in the liver) tissue uptake and elimination
via the kidney [31]. We recently showed inmdxmice that systemic
taurine homeostasis is perturbed and may correlate with the onset
of pathology [31], and treatment of adult mdx mice with taurine
improves both in vivo and ex vivo muscle strength [23,32,33].
Importantly, in young mdx mice aged 22 days, taurine treatment
(from day 14) prevents the acute onset of myoﬁbre necrosis [34].
Taurine is hypothesised to modulate ion channel function, mem-
brane stability and calcium homeostasis [35–40]. However we
showed that taurine is also a potent thiol antioxidant in mdx
muscle and can dramatically decrease muscle tissue content of
neutrophils and myeloperoxidase (MPO) [23,34]. MPO is a heme
protein secreted primarily by neutrophils, the key cells involved in
acute inﬂammation that are phagocytes responsible for microbial
killing and generation of various pro-inﬂammatory mediators that
attract macrophages to the site of tissue damage [41]. MPO is also
secreted (to a lesser extent) by monocytes and can be secreted by
some macrophages [42]. MPO oxidises chloride in the presence of
hydrogen peroxide to form the potent oxidant hypochlorous acid
(HOCl) that targets proteins by reacting with thiols and by causing
oxidative damage [43]. Amino acids such as taurine can function as
antioxidants by forming chloramines which can trap HOCl [41].We propose that a possible mechanism for elevated oxidative
stress in dystrophic muscles is the excessive generation of HOCl
(by inﬂammatory cells), combined with a disruption in taurine
metabolism, that leaves tissues susceptible to oxidative damage by
HOCl.
The golden retriever muscular dystrophy (GRMD) dog model
manifests a more severe dystropathology with a rapidly progres-
sing and fatal disease similar to DMD boys, in marked contrast
with the mdx mouse model [43]. The disruption in taurine meta-
bolism documented for mdx mice has the potential to be species
speciﬁc, since the homeostasis of taurine differs greatly between
carnivores such as dogs and humans, and mice [44]. Furthermore,
compared with GRMD dogs and DMD boys, the mdx mice exhibit a
very mild pathology, possibly due to the very short growth phase
and lifespan as well as the small size of mdx mice [3,45]. Like the
human DMD condition, persistent muscle necrosis in GRMD dogs
results in incomplete muscle repair leading to loss of myoﬁbres
and increased ﬁbrosis, with progressive weakness and gait ab-
normalities around 6–9 weeks of age and contractures by
6 months [46]. Death of GRMD dogs usually occurs around 1 year
of age as a result of failure of respiratory muscles as well as feeding
difﬁculties (severe dysphagia) [43,47,48]. Whilst dystrophin deﬁ-
ciency has now been identiﬁed in many breeds of dogs [49], GRMD
dogs are the favoured model for pre-clinical trials in DMD research
[46,51,52], although the colonies are expensive and hard to
maintain and show high variation between individual dogs [50].
There is little information on the role of oxidative stress in GRMD
muscles and the role of taurine in GRMD dystropathology has yet
to be investigated; however it is known that diet induced taurine
deﬁciency predisposes healthy dogs to cardiomyopathy [51].
The present study investigated inﬂammation, oxidative stress
and taurine homeostasis in muscle and blood from GRMD and
healthy wild-type dogs, to determine whether taurine deﬁciency
in GRMD dogs may render the dystrophic muscles susceptible to
oxidative damage and protein thiol modiﬁcations, caused by in-
ﬂammation. Inﬂammation was assessed in GRMD and healthy dog
muscles by quantifying the presence of neutrophils and macro-
phages; the contribution of these cells to oxidative stress was as-
sessed by measuring MPO and chlorotyrosines, which are bio-
markers of HOCl generation [52]. Oxidative stress was quantiﬁed
by measuring levels of protein thiol oxidation (including the thiol
oxidative status of speciﬁc abundant proteins) and protein carbo-
nylation. Taurine can accumulate in cells through two mechan-
isms; by uptake from the extracellular space by the sodium de-
pendent transporter TauT, and by endogenous local synthesis from
cysteine by two enzymes, cysteine deoxygenase and cysteine
sulﬁnate decarboxylase [29,53]. Since we have previously shown
that both mechanisms are perturbed in mdx muscle [31], we
measured TauT, cysteine deoxygenase and cysteine sulﬁnate dec-
arboxylase in GRMD muscle, as well as taurine content of the
muscle and plasma (to establish extracellular taurine concentra-
tions). We show that GRMD muscle has an increased content of
neutrophils and macrophages with resultant high levels of MPO
and HOCl, associated with high levels of protein thiol oxidation
and irreversible oxidative damage of both intracellular and ex-
tracellular proteins; we also show perturbations of taurine
homeostasis in GRMD dogs. These data emphasise the value of
using GRMD dogs to evaluate the role of immune cell generated
HOCl in dystropathology, and support the use of this dystrophic
dog model for pre-clinical trials of interventions that target this
pathway.
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2.1. Animal procedures
Muscle and plasma samples were obtained from 4 healthy
control (unaffected normal) male golden retriever dogs and
5 GRMD male dogs, aged approximately 8 months. These dogs
were handled and housed in the Boisbonne Center for Gene
Therapy (ONIRIS, Atlantic Gene Therapies, Nantes, France). The
Institutional Animal Care and Use Committee of the Region des
Pays de la Loire (University of Angers, France) approved all these
protocols. Skeletal muscles samples (biceps femoris) were ob-
tained after the dogs were sacriﬁced, performed by intravenous
injection of pentobarbital sodium (Dolethal, Vetoquinol). Muscle
samples were placed into sterile microtubes, frozen in liquid ni-
trogen and subsequently stored at about 80 °C until analysis.
Plasma samples were obtained after blood collection in EDTA-
coated tubes. Within 15 min, the tubes were centrifuged 8 min at
3000 rpm to obtain plasma. Plasma samples were stored at about
80 °C until analysis.
2.2. Muscle protein extraction and immunoblotting
Frozen muscles were crushed using a mortar and pestle under
liquid nitrogen and homogenized in 10 times ice-cold 1% NP40,
1 mM EDTA in phosphate buffered saline (PBS), supplemented
with complete EDTA free protease inhibitor tablets and PhosSTOP
phosphatase inhibitor tablets (Roche), and centrifuged for 10 min.
The protein concentration of supernatants was quantitated using
the Detergent Compatible (DC) protein assay (Bio-Rad). Samples
were resolved on 4–15% SDS-PAGE (sodium dodecyl sulphate
polyacrylamide gel electrophoresis) TGX gels (Bio-Rad) and
transferred onto nitrocellulose membrane using a Trans Turbo Blot
system (Bio-Rad). Immuno-blotting was performed with anti-
bodies to neutrophil elastase (ab68672, Abcam), macrophage F4/
80 (ab74383, Abcam), myeloperoxidase (14,569, Cell Signalling),
cysteine dioxygenase type 1 (ab53436, Abcam), cysteine sulﬁnate
decarboxylase (ab101847, Abcam), TauT (TAU11-A, Alpha Diag-
nostics) and glyceraldehyde 3-phosphate dehydrogenase (GAP,
14C10, Cell Signalling), all dissolved 1:1000 in 5% bovine serum
albumin (BSA). Horseradish peroxidase conjugated secondary an-
tibodies were from Thermo Fisher Scientiﬁc. Chemiluminescence
signal was captured using the ChemiDoc MP Imaging System (Bio-
Rad). Resultant images were quantiﬁed using ImageJ software [54].
Glyceraldehyde 3-phosphate dehydrogenase (GAP) loading con-
trols were immunoblotted on the same membrane as the im-
munoblotted protein. All representative immunoblots in ﬁgures
represent proteins immunoblotted on the same membrane as the
loading control GAP.
2.3. Chlorinated tyrosines
Tyrosine and chlorinated tyrosines in proteins from muscle
extracts were determined as previously described [55] using stable
isotope dilution liquid chromatography with mass spectrometry
instead of gas chromatography. In brief, frozen muscles were
crushed using a mortar and pestle under liquid nitrogen, homo-
genized in 20% methane sulfonic acid in acetone and, after cen-
trifugation, supernatants were removed and pellets dried by va-
cuum centrifugation. 13C6 and 13C9 Tyrosine and 13C6 chlorotyr-
osine internal standards were added to samples containing 80 μg
of protein (as determined by the DC protein assay, Bio-Rad) to
allow stable isotope quantiﬁcation and determine any artiﬁcial
chlorination. Samples were hydrolysed for 18 h at 110 °C in 6 M
hydrogen bromide. The hydrolysates were diluted in 0.1% formic
acid and tyrosine derivatives were isolated using a Dionex 3000high performance liquid chromatography (HPLC) pump with a C18
Gemini column (1002.00 mm, 3 mm). A reverse phase gradient
elution using 0.1% formic acid in water and 0.1% formic acid in
acetonitrile was used for elution of analytes. Analytes were de-
tected on a 4000QTRAP mass spectrometry using Multiple Reac-
tion Monitoring for the tyrosine and chlorotyrosine isotopes.
2.4. Quantiﬁcation of protein thiol oxidation
Reduced and oxidized protein thiols were measured in muscles
using the 2 tag technique as described previously [14,18–22]. In
brief, frozen tissue was crushed under liquid nitrogen, before
protein was extracted with 20% trichloroacetic acid (TCA) in
acetone. Protein was solubilized in 0.5% SDS with 0.5 M Tris at pH
7.3 (SDS buffer) and protein thiols were labelled with the ﬂuor-
escent dye BODIPY FL-N-(2-aminoethyl) maleimide (FLM, In-
vitrogen). Following removal of the unbound dye using ethanol,
protein was re-solubilized in SDS buffer, pH 7 and oxidized thiols
were reduced with tris(2-carboxyethyl)phosphine (TCEP) before
the subsequent unlabeled reduced thiols were labelled with a
second ﬂuorescent dye Texas Red C2-maleimide (Texas red, In-
vitrogen). The sample was washed in ethanol and resuspended in
SDS buffer. Samples were read using a ﬂuorescent plate reader
(Fluostar Optima) with wavelengths set at excitation 485 nm,
emission 520 nm for FLM and excitation 595 nm, emission 610 nm
for Texas red. A standard curve for each dye was generated using
ovalbumin and results were expressed per mg of protein, quanti-
ﬁed using the DC protein assay (Bio-Rad).
Reduced and oxidized thiols of speciﬁc proteins were quanti-
ﬁed using a 1-dimensional SDS–PAGE, as described previously [19].
Brieﬂy, labelled samples (remaining from plate assay above) were
diluted to equivalent protein concentrations. FLM and Texas red
labelled BSA standards were combined and both the standards and
samples were diluted by the addition of sample buffer (125 mM
Tris, pH 6.8, 4% SDS, 30% (v/v) glycerol, 0.02% bromophenol blue).
Standards and samples were applied to a 12% polyacrylamide gel.
Gel electrophoresis was performed using the Bio-Rad Mini Protean
III system. Each ﬂuorescent gel was scanned using the ChemiDoc
MP Imaging System (Bio-Rad) for ﬂuorescence, with wavelengths
set at excitation 485 nm, emission 520 nm for FLM and excitation
595 nm, emission 610 nm for Texas red. The bands were quantiﬁed
by densitometry using ImageJ version 1.41 software [54] using the
integrated density function, after ﬁrst removing the background.
To assess the reversible protein thiol oxidation state of speciﬁc
protein bands, dominant bands were compared against FLM and
Texas red using in-gel standard curves using polynomial regres-
sion. Non-labelled samples were run in parallel in the same gel,
and after gel scanning, gels were stained with Coomassie brilliant
blue, scanned and speciﬁc protein bands of interest were excised
for mass spectrometry.
2.5. Mass spectrometry to identify speciﬁc proteins
Gel bands were excised for in-gel digestion, and cut into 1 mm
cubes. Gel pieces were de-stained 3 times with 100 μl of 25 mM
ammonium bicarbonate in 50% acetonitrile (ACN) at 37 °C for
30 min. Gel pieces were then dried by vacuum centrifugation.
Protein was digested by addition of 125 ng trypsin in 10 μl of
25 mM ammonium bicarbonate. The digestion reaction proceeded
at 37 °C for 16 h. Digested protein was extracted by 3 additions of
20 μl 1% triﬂouroacetic acid in ACN and incubation at room tem-
perature for 20 min. Extracts were pooled and desiccated by va-
cuum centrifugation.
Extracts were reconstituted in 11 μl of 2% ACN, 0.1% formic acid
(FA) solution for loading into a Prominence (Shimadzu) HPLC for
chromatographic separation, which was directly sprayed into a
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phase consisted of 0.1% (FA and 2% ACN in water (A) and 0.1% FA
and 2% water in ACN (B). Gradient elution was performed with 2%
B for 3 min, increased to 40% B at 15 min, then ramped to 98% B by
16 min and held for 1 min before reduced back to 2% B within
1 min. Column temperature was 40 °C. Positive electrospray ioni-
zation mode was operated to acquire MS data by information-
dependent acquisition (IDA), where only the top 20 MS peaks
between 400 and 1250m/z were selected for further MS/MS scan.
Mass tolerance was 50 mDa. BSA calibration was conducted before
a batch of samples was run. Parent mass peaks (mass range m/z
800–3000 from combined MS and MS/MS spectra) were submitted
to the MASCOT database for identiﬁcation of peptides, using the
following search conditions: Swissprot database, all mammalian
species, trypsin digest with allowance for up to one missed clea-
vage per peptide, no ﬁxed modiﬁcations, variable modiﬁcation of
oxidation on methionine residues, MS tolerance of 1.2 Da, MS/MS
tolerance of 0.6 Da. Proteins were identiﬁed on the basis of 2 or
more peptides with ion scores exceeding the signiﬁcance
threshold.
2.6. Carbonylated protein
Irreversible oxidative damage to proteins in muscle was de-
termined by measuring the carbonyl content with 2,4-dini-
trophenylhydrazine (DNPH) as previously described [20,56,57]. In
brief, frozen muscles were crushed under liquid nitrogen, before
protein was extracted with 20% TCA/acetone. The protein pellets
were washed in acetone and ethanol, precipitated, dried, re-sus-
pended in 10 mM DNPH in 2 M HCl and incubated for 30 min at
room temperature in the dark. Proteins were washed with ethyl
acetate/ethanol (1:1), dissolved in 6 M guanidine, and absorbance
was measured at 370 nm. Protein concentration (mg/ml) was de-
termined using the Bio-Rad Bradford protein assay. Carbonyl
concentrations are expressed as nmol of carbonyl per mg protein.
2.7. HPLC analysis of taurine
Taurine levels in muscle and plasma were measured using re-
verse phase HPLC as previously described [19]. Frozen tissues were
crushed using a mortar and pestle under liquid nitrogen and
homogenized in 25 times 5% TCA, plasma samples were pre-Fig. 1. Neutrophil (A) and macrophage (B) levels in muscles of healthy and GRMD dog
presented as mean7SEM and n¼4 and 5 respectively. Representative blots are shown
dehydrogenase (GAP), all proteins were blotted on the same membrane.cipitated by addition of 10 times 5% TCA and, after centrifugation,
supernatants were removed and stored at 80 °C before analysis.
Analytes were separated using HPLC with ﬂuorescent detection,
with pre-column derivitisation with o-phthalaldehyde (OPA) and
2-mercaptoethanol (2ME). OPA reacts rapidly with amino acids
and sulfhydryl groups to yield intensely ﬂuorescent derivatives,
and 2ME, a reducing agent, prevents the OPA reagent from oxi-
dising. Supernatants were mixed with iodoacetamide, dissolved in
5% TCA, to a ﬁnal concentration of 25 mM. An internal standard,
o-phospho-dl-serine, dissolved in 5% TCA was added to a ﬁnal
concentration of 5 mM. Sodium borate was used to adjust the pH
to 9. Samples were placed in an autosampler, which was main-
tained at 4 °C. Samples were mixed on a sample loop with a de-
rivatising solution containing 40 mM OPA and 160 mM 2ME in
100 mM sodium borate, pH 12, for 30 s before injection onto the
column. Separation was achieved with a C18 column (5 μl,
4.6150 mm, Phenomenex) using a Dionex Ultimate 3000 HPLC
system. Mobile phase A consisted of 50 mM potassium phosphate
buffer, methanol and tetrahydrofuran (94:3:3). Mobile phase B
consisted of 90% methanol, with a gradient increase in B from 0%
to 25%. Fluorescence was set at 360 nm and 455 nm for excitation
and emission respectively. The protein content of muscle samples
were quantiﬁed by solubilising the pellet in 0.5 M sodium hydro-
xide, before incubation at 80 °C for 15 min. Once fully dissolved,
protein concentrations of supernatants were quantiﬁed using a
Bradford protein assay (Bio-Rad).
2.8. Statistics
Signiﬁcant differences between groups were determined using
t-tests and all data are presented as mean 7 standard error of the
mean (SEM). Signiﬁcance was set at po0.05.3. Results
3.1. Neutrophil and macrophage quantiﬁcation
Quantiﬁcation of neutrophils and macrophages in healthy
(normal control) and GRMD dog muscle was measured by western
blotting for the proteins neutrophil elastase and F4/80; both
considered speciﬁc for neutrophils and macrophages, respectivelys aged 8 months. Asterisks represent signiﬁcant differences of po0.05. Data are
of neutrophil elastase, F4/80 and the loading control glyceraldehyde 3-phosphate
J.R. Terrill et al. / Redox Biology 9 (2016) 276–286280[58]. The levels of neutrophils (Fig. 1A) and macrophages (Fig. 1B)
in GRMD muscle were 35 and 9 fold higher (respectively) than for
healthy control dog muscle.
3.2. Chlorinated tyrosines and myeloperoxidase
The formation of HOCl is catalysed by MPO (likely produced by
neutrophils and macrophages). MPO content of GRMD muscle was
33 fold higher than healthy control dog muscle (Fig. 2A). EvidenceFig. 2. Myeloperoxidase (MPO) (A) and chlorotyrosines (B) in muscles of healthy and GR
as mean7SEM and n¼4 and 5 respectively. Representative blots are shown of MPO and
were blotted on the same membrane.
Fig. 3. Total protein thiols (A), percentage of protein thiol oxidation (B) and protein ca
differences of po0.05. Data are presented as mean7SEM and n¼4 and 5 respectivelyof HOCl generation was determined by measuring chlorotyrosines
(which are formed when tyrosyl residues of peptides are exposed
to HOCl [59]). Chlorinated tyrosines were 1.4 fold higher in GRMD
muscle compared with healthy control dog muscle (Fig. 2B).
3.3. Protein oxidation
Measurements of (reversible) oxidation of thiol side chains in
proteins showed that the total amount of protein thiols was 22%MD dogs. Asterisks represent signiﬁcant differences of po0.05. Data are presented
the loading control glyceraldehyde 3-phosphate dehydrogenase (GAP), all proteins
rbonylation in muscles of healthy and GRMD dogs. Asterisks represent signiﬁcant
.
Table 1
Protein thiol oxidation of abundant proteins in healthy and GRMD muscle. Asterisks
represent signiﬁcant differences of po0.05. Data are presented as mean7SEM and
n¼4 and 5 for healthy and GRMD dogs respectively.
Protein name Accession # # Sig.
peptides
Healthy dogs GRMD dogs
Myosin Q076A6 8 11.071.5 30.873.8*
Myosin-binding protein
C
Q00872 18 17.570.9 34.072.9*
Sarcoplasmic/reticulum
calcium ATPase
O14983 9 15.370.8 30.572.8*
Lactoferrin P02788 26 27.372.6 65.774.6*
Albumin P49822 33 13.070.8 31.773.0*
Phosphoglucomutase Q08DP0 5 12.970.8 31.072.8*
Pyruvate kinase P11980 5 11.270.8 24.071.8*
Myotilin Q9UBF9 8 12.871.0 25.872.5*
Glyceraldehyde-3-phos-
phate dehydrogenase
Q28259 13 10.071.3 15.271.7*
Malate dehydrogenase P08249 8 8.670.9 18.772.3*
Alpha actin P68138 87 4.770.6 5.570.6
Creatine kinase P05123 47 8.670.9 8.670.9
J.R. Terrill et al. / Redox Biology 9 (2016) 276–286 281lower (Fig. 3A), whereas total protein thiol oxidation was 1.8 fold
higher (Fig. 3B) in GRMD, compared with healthy control, dog
muscle. The status of thiol oxidation of speciﬁc abundant proteins
was also determined. As shown in Table 1, among the 12 proteins
identiﬁed, 10 had signiﬁcantly more protein thiol oxidation (from
1.5 to 2.8 fold) in GRMD muscle compared with healthy dog
muscle. The identiﬁed proteins that underwent thiol oxidation in
GRMD muscle included myosin, myosin-binding protein C, myo-
tilin, sarcoplasmic reticulum ATPase, pyruvate kinase, malate de-
hydrogenase, phosphoglucomutase, glyceraldehyde-3-phosphate
dehydrogenase, lactoferrin and albumin.
Irreversible protein damage in GRMD muscle (measured by
carbonylation of protein), was 4.7 fold higher in GRMD muscle,
compared with healthy control dog muscle (Fig. 3C).
3.4. Taurine homeostasis
Taurine content of muscle and plasma from healthy control and
GRMD dogs was determined using HPLC. Compared with healthy
dogs, taurine content was 1.6 fold higher in GRMD muscle
(Fig. 4A); however, plasma taurine content was 27% lower in
GRMD dogs (Fig. 4B). Since intracellular taurine content depends
on transport of taurine into the cells via the transporter protein
TauT, combined with the synthesis of taurine from cysteine by theFig. 4. Taurine content of healthy and GRMD muscles (A) and plasma (B). Asterisks repre
and 5 respectively.enzymes cysteine deoxygenase and cysteine sulﬁnate decarbox-
ylase, levels of these proteins in muscle were measured by wes-
tern blotting. Levels of TauT (Fig. 5A), cysteine deoxygenase
(Fig. 5B) and cysteine sulﬁnate decarboxylase (Fig. 5C) were, re-
spectively, 12, 8 and 35 fold higher in GRMD muscle compared
with healthy dog muscle, indicating that both transport and
synthesis of taurine are upregulated in GRMD muscle (to likely
account for the high levels of taurine that are present).4. Discussion
Our key observations (summarised in Table 2) are that, com-
pared with normal control dogs, dystrophic muscles of GRMD dogs
contain signiﬁcantly higher levels of neutrophils and macrophages
and associated HOCl, and irreversible and reversible protein oxi-
dation. In addition, taurine homeostasis is perturbed in GRMD
muscles and plasma, with the deﬁciency in GRMD plasma taurine
levels potentially rendering dystrophic muscles more susceptible
to protein oxidation. These novel data for dystrophic dogs are
discussed in detail below.
We show increased content of neutrophils and macrophages in
GRMD muscle. In skeletal muscle, the neutrophils and macro-
phages (that invade skeletal muscle after injury such as myone-
crosis) phagocytose and remove necrotic cellular debris, are che-
motactic, result in modiﬁcation of the extracellular matrix (ECM)
and play key roles in promoting all aspects of myogenesis and the
regeneration of the necrotic myoﬁbres [60–63]. Upon stimulation,
neutrophils (that begin accumulating within 30 min of muscle
damage) and macrophages undergo a burst of oxygen consump-
tion caused by the NAD(P)H oxidase complex in the phagosomal
membrane, which stimulates the generation of superoxide [64].
Superoxide is dismuted to form hydrogen peroxide, which can
undergo a Fenton reaction with a metal catalyst to form the highly
reactive hydroxyl radical. However, the protein lactoferrin (an iron
binding glycoprotein) found in neutrophils, sequesters free iron
thus inhibiting production of this damaging hydroxyl radical [65].
Another protein that determines the fate of hydrogen peroxide is
MPO, which consumes hydrogen peroxide more rapidly than the
Fenton reaction [64]. MPO can also oxidise chloride in the pre-
sence of hydrogen peroxide to form HOCl, a highly reactive oxi-
dant. Proteins are major targets for HOCl, and reactions result in
thiol modiﬁcations as well as protein damage [66]. We show that
both MPO content and HOCl generation are increased in GRMD
muscle and that this is associated with elevated protein thiolsent signiﬁcant differences of po0.05. Data are presented as mean7SEM and n¼4
Fig. 5. TauT (A), cysteine deoxygenase (CD) (B) and cysteine decarboxylase (CSD) in muscles of healthy and GRMD dogs. Asterisks represent signiﬁcant differences of
po0.05. Data are presented as mean7SEM and n¼4 and 5 respectively. Representative blots are shown of TauT, CD, CSD and the loading control glyceraldehyde
3-phosphate dehydrogenase (GAP), all proteins were blotted on the same membrane.
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most frequently used biomarker of irreversible protein oxidative
damage [67], and is elevated in many conditions, including in-
ﬂammatory disorders such as chronic lung disease, inﬂammatory
bowel disease, rheumatoid arthritis and sepsis [68]. Direct oxida-
tion of proteins by HOCl yields highly reactive carbonyl deriva-
tives, resulting from oxidation of amino acid side chains or from
the cleavage of peptide bonds leading to the formation of protein
derivatives or peptide fragments containing highly reactive car-
bonyl groups [69]. HOCl also reacts rapidly with thiol groups, and
can cause reversible modiﬁcations, however being a strong oxi-
dant, HOCl can also react with thiols to form irreversible products
[70,71]. These modiﬁcations were likely evident in the current
study, where GRMD muscle showed high reversible thiol oxidation
for many proteins, and a reduction in total protein thiols.
Since protein thiol modiﬁcations affect protein (and therefore
tissue) function, we identiﬁed speciﬁc proteins that underwent
thiol oxidation in GRMD muscles (using SDS-PAGE and massspectrometry). These diverse proteins were located throughout
the cell, and included vital contractile proteins of the sarcomeres
(myosin, myosin-binding protein C, myotilin), sarcoplasmic re-
ticulum (sarcoplasmic reticulum ATPase), mitochondria (pyruvate
kinase and malate dehydrogenase), cytoplasm (phosphoglucomu-
tase and glyceraldehyde-3-phosphate dehydrogenase) and extra-
cellular ﬂuid (lactoferrin and albumin). In skeletal muscle, con-
tractile function, force production and the development of fatigue
are directly inﬂuenced by the redox state of thiol side chains of
contractile proteins [72–78]. For example, thiol oxidation of myo-
sin, as we observed in GRMD muscle, affects contraction by de-
creasing myosin ATPase activity, decreasing Ca2þ sensitivity and
modifying kinetics of actin-myosin cross bridge transitions
[74,75,79–81]. The myosin-binding protein C contributes to the
assembly and stability of thick ﬁlaments and regulates the cross-
bridge interactions of myosin and actin [82], and myotilin is also
important for organisation of the myoﬁbril [83]: both these pro-
teins had increased thiol oxidation in GRMD muscle. While the
Table 2
Summary of differences in GRMD tissues (compared with normal control dogs).
Parameter measured Increase ↑ or decrease
↓
Fold change
Inﬂammation in muscle
Neutrophils ↑ 35
Macrophages ↑ 9
Oxidative stress in muscle
MPO ↑ 33
HOCL ↑ 1.4
Total protein thiols ↓ -1.3
% Total protein thiol oxidation ↑ 2.8
Thiol oxidation in 10/12 speciﬁc
proteins
↑ 2
Protein carbonylation ↑ 1.4
Taurine metabolism
Muscle taurine ↑ 4.7
Plasma taurine ↓ 1.4
Muscle TauT ↑ 12
Muscle cysteine deoxygenase ↑ 8
Muscle cysteine decarboxylase ↑ 35
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understood in skeletal muscle, oxidative modiﬁcation of thiol
groups of myosin-binding protein C controls the response of
myoﬁlaments to calcium in cardiac tissue [84].
In GRMD muscles, other intracellular proteins with elevated
thiol oxidation included: sarcoplasmic/endoplasmic reticulum
calcium ATPase (SERCA) that is a key regulator of muscle con-
tractile activity responsible for the reuptake of cytosolic Ca2þ into
the sarcoplasmic reticulum [85]; phosphoglucomutase, a protein
with roles in glucose metabolism including glycogenolysis and
glycogenesis [86]; pyruvate kinase that catalyzes the last but rate-
limiting step of glycolysis [87]; and glyceraldehyde-3-phosphate
dehydrogenase- a membrane protein involved in a variety of cel-
lular processes including glycolysis and malate dehydrogenase,
which is utilised in numerous metabolic pathways. Previous re-
search shows that thiol oxidation of these proteins can directly
effect their functions [88–93]. While the consequences of high
thiol oxidation of these diverse proteins in GRMDmuscle are yet to
be fully understood and appreciated, functional changes in these
proteins and downstream cellular consequences may well con-
tribute to severity of dystropathology in GRMD dogs. Thus there is
considerable interest in reversing this high level of protein thiol
oxidation as a therapeutic strategy.
Interestingly, we also identiﬁed two extracellular proteins,
lactoferrin and albumin, with increased protein thiol oxidation in
GRMD muscle. A role for lactoferrin in preventing hydroxyl radical
production has been identiﬁed [65], but the consequences of thiol
oxidation on the function of this highly cysteine rich protein has
not been described. Lactoferrin contains 33 cysteine residues in-
cluding many intramolecular disulphide bonds [94]. Albumin
contains one reduced cysteine residue and is considered an im-
portant circulating thiol antioxidant since it is the most abundant
plasma protein (representing about 50–60% of all plasma proteins
in rodents and humans) [95,96]. In healthy humans, abundant
albumin is also localised extravascularly in the interstitial ﬂuid,
with the amount of albumin being more than double that within
the intravascular plasma, suggesting that albumin is likely espe-
cially important as a thiol regulator in extracellular ﬂuids in in-
timate contact with the surface of cells [97]. Our novel GRMD data
show that alterations and regulation of oxidative stress occurs
both inside and outside the myoﬁbre, supporting the hypothesis
that extracellular sources of oxidants (such as generated by im-
mune cells) may signiﬁcantly increase oxidative stress at the lo-
cation of the sarcolemma in GRMD.Investigating taurine homeostasis in GRMD muscle in con-
junction with measuring protein oxidation and inﬂammation is of
interest as we have previously shown taurine homeostasis is
perturbed in mdx mice [31], and taurine treatment decreased
protein thiol oxidation, neutrophil and MPO content in mdx
muscle, and prevented myoﬁbre necrosis [23]. The antioxidant and
anti-inﬂammatory properties of taurine are attributed to its ability
to interact with HOCl, which reacts with amino acids to form long-
lived chloramines such as taurine chloramine; chloramines are
much less reactive than HOCl [41]. Unlike HOCl, chloramines dis-
criminate between low molecular weight thiols based on their pKa
[98] and thus chloramines cannot oxidise as many molecules as
HOCl. Taurine chloramine also exerts anti-inﬂammatory effects
such as inhibiting the production of pro-inﬂammatory cytokines
and nitric oxide (NO), and appears to inhibit NF-κB activation by
the oxidation of IκB-α [41,99].
We and others have observed that taurine content of dys-
trophic mdx muscle is variable across the age (and stage of disease
progression) [31,34,100]. Whilst the timing and muscles used in
these different mdx studies is variable, early in the disease pro-
gression (before 6 weeks) mdx muscles have low taurine content,
with taurine content increasing with age. In one study, adult (46
week) mdx muscle had increased taurine content compared with
wild-type muscle [100]. These data suggest that taurine content of
mdx muscle increases with stabilisation of pathology. Our study
shows that GRMD dogs aged 8 months have increased muscle
taurine content, despite already accumulating severe dystro-
pathology. This level of taurine may be a feature of adult dys-
trophic muscles, since taurine levels are lower in juvenile mdx
mice (aged 18 days) during the intensive growth phase, associated
with the time when onset of muscle necrosis is pronounced; it
may be of interest to examine taurine levels and metabolism in
much younger GRMD dogs. Regardless, these data do not support
our hypothesis that a taurine deﬁciency in GRMD muscle may
render the muscle more susceptible to oxidative stress. However,
since taurine is found in high concentrations in tissues exposed to
elevated levels of oxidants [99], the increased taurine content of
GRMD muscle aged 8 months may reﬂect an upregulation of
taurine (due to increased taurine requirements). This is reﬂected
in the upregulation of TauT, cysteine deoxygenase and cysteine
sulﬁnate decarboxylase we observed in GRMD muscle. Interest-
ingly, this was not observed in mdx mice, where we have pre-
viously described downregulation of TauT in both young (18 day)
and adult (6 week) mdx muscle, and a downregulation of cysteine
deoxygenase at 4 weeks of age [31].
A further species difference is that while plasma of adult mdx
mice has normal levels of taurine [31], GRMD plasma is deﬁcient
in taurine. This deﬁciency in plasma taurine may reﬂect increased
taurine excretion in the kidney or decreased taurine synthesis in
the liver, that is observed in juvenile mdxmice [31], however these
parameters were not examined in the dystrophic dogs (since liver
and kidney tissue was not available). It has also been suggested
that after an injury, activated neutrophils sequester taurine from
the plasma to the site of injury, leading to a drop in plasma taurine
concentrations [101]. Therefore the differences observed (in both
muscle and plasma values) between the mdx and GRMD animals
may reﬂect the striking contrast in severity of pathology at the
ages examined for these species.
The differences may also relate to striking interspecies differ-
ences in neutrophil content of blood, since neutrophils represent
only a relatively very small proportion, 10–25%, of leucocytes in
mice, whereas neutrophils are far more prevalent in dog and hu-
man blood, where they represent about 70% and 50–70% (re-
spectively) of leucocytes [102,103]. This is an important point since
the much higher neutrophil levels in dogs (and humans), and the
35 fold increase of neutrophils in GRMD muscles, implies a much
J.R. Terrill et al. / Redox Biology 9 (2016) 276–286284greater role for the adverse effects of neutrophils in the severity of
dystropathology in dogs and humans.5. Conclusions
Our data emphasise the value of the use of GRMD dogs in the
evaluation of the role of immune cell-generated HOCl in dystro-
pathology, and suggest that the dystrophic dogs are a particularly
useful model for pre-clinical trials of interventions that target this
pathway. Our data suggest that taurine homeostasis is regulated in
a different manner in dystrophic dogs (compared with mdx mice)
and this information, combined with the similar high neutrophil
content of dog and human blood emphasises the importance of
using the GRMD dog model for pre-clinical testing of therapies
such as taurine. However, it is not apparent whether taurine
treatment will be beneﬁcial for GRMD dogs; whilst GRMD plasma
is deﬁcient in taurine, GRMD muscle exhibits excess taurine, and it
not clear whether it is intracellular or vascular taurine that is
important for targeting HOCl in GRMD muscle. Future research is
required to better describe the metabolism of taurine in GRMD
dogs at different stages of dystropthology, to understand the use of
taurine in preventing myonecrotic damage caused by in-
ﬂammatory cell generated oxidants, and to evaluate the potential
of taurine as a suitable therapeutic intervention for DMD boys.Conﬂict of interest statement
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